The Dean Tells Students Why Not To Wait On VRAL
July 20th, 2009 at 11:30 am Posted by The Dean
Instead of just sitting around and thinking of ways not to get in on $VRAL, The Dean’s here to tell you to get in early and do your homework before Phase 1 FDA trials begin for the VGV-1 injectable drug. There have been a couple of surges on $VRAL that many of The Dean’s Honors Students have already cashed in on.
Did you know that there were over 550,000 cancer deaths last year in the United States alone?
Even more striking, is that over 30 million people in the world are living with HIV and AIDS. With that many people infected, the figures grow in number each year. In fact, over the past 5 years, 2 million HIV and AIDS related deaths have been recorded on average each year.
Now, The Dean isn’t here to dwell in the negative. There are no limits to where positive thinking can take you, especially in the speculative market.
Rather, The Dean is here to tell you that $VRAL is not only researching and developing drugs and treatments for infectious, autoimmune and immunological deficiency diseases, but they are also working to pursue and identify specific proteins that will help in the early-detection of HIV and cancer. Detection and treatment? It sounds to me like they are not playing around. And you shouldn’t either.
It’s clear to The Dean that $VRAL is serious about finding solutions to help people live longer, healthier lives. Diseases such as HIV/AIDS and cancer are not going anywhere anytime soon. But with the types of medical advancements and product development in store at Viral Genetics, Inc., you can be sure that $VRAL is a smart pick.
